Last edition
News about Clinical Trials
NeuroSense Reports Positive Phase 2 Biomarker Results for PrimeC in Alzheimer's Disease Trial
PrimeC shows encouraging biomarker activity in Phase 2 Alzheimer’s study, supporting its potential as a multi-target therapy for neurodegenerative diseases.
Clinical Trials | 26/06/2026 | By News Bureau
HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.
Clinical Trials | 26/06/2026 | By News Bureau
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
Clinical Trials | 23/06/2026 | By News Bureau
CureGene Doses First Patient in Pivotal US Trial of Evategrel
CureGene achieves first participant dosed in US pivotal trial for Evategrel (CG-0255), a best-in-class antiplatelet drug, accelerating global commercialisation.
Clinical Trials | 23/06/2026 | By News Bureau
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction
Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).
Clinical Trials | 23/06/2026 | By News Bureau
Mabwell Presents Clinical Data for Nectin-4 ADC 9MW2821 at ESMO 2026
Clinical studies presented at the 2026 ESMO Gynecological Cancers Congress showed that Mabwell’s Nectin-4-targeting ADC 9MW2821 demonstrated a manageable safety profile, promising efficacy, and notable survival benefits in cervical cancer patients, with encouraging antitumor activity when combined with a PD-1 inhibitor.
Clinical Trials | 20/06/2026 | By News Bureau
Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.
Clinical Trials | 18/06/2026 | By News Bureau
Suven Life Sciences reported positive phase 2b results for Ropanicant in Major Depressive Disorder (MDD), achieving significant improvements in depression symptoms versus placebo. The treatment showed favorable safety and tolerability, with no withdrawal symptoms or dissociation, supporting advancement into a global phase 3 study.
Clinical Trials | 17/06/2026 | By News Bureau
Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1
Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.
Clinical Trials | 16/06/2026 | By News Bureau
Suven Life Sciences Reports Positive Phase 1 Results for SUVN-I6107
Suven Life Sciences has reported positive topline results from the First-in-Human phase 1 study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM). The successful trial supports the advancement of SUVN-I6107 into phase 2 clinical development.
Clinical Trials | 16/06/2026 | By News Bureau | 101
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy